BridgeBio Oncology Therapeutics, Inc. BBOT
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting RAS and PI3Kα pathway cancers. The company specializes in precision oncology by creating innovative approaches to address historically difficult-to-drug targets, including direct KRAS inhibitor…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees106
TickerBBOT
Statistics
Market Cap$614.3M
Revenue (TTM)$0
Net Income-$134.0M
Net Margin—
EPS$-4.30
P/E-1.73
P/S—
P/B1.53
EV/EBITDA-1.90
ROE-62.2%
Dividend Yield—
Price$7.67
Data: Twelve Data · Revenue = mcap / P/S